I've spent the past couple days reading through th

I've spent the past couple days reading through the preliminary Reg A+ filing. There may be a few typos and misplaced decimal points, but I didn't see any material errors.

However, I did notice the Board increased the authorized amount of shares that can be issued to 500 million from 400 million. If the company wants to offer the additional maximum amount of 500 million shares at $0.01 in this offering, the Board would need to approve another 300 million share increase.

I'm also asking myself what's the point of raising $5M when there's a $30M+ hole in the balance sheet. I'm now starting to wonder if this Reg A+ is really about raising $5M. Maybe it's about something else.

For example, what if it's about putting the company under new ownership. Earlier this year, Gerald mentioned in a "2019 Roadmap" press release that the company was looking for senior leadership candidates to take over daily operations. New leadership could come from a potential acquirer of AMBS.

I find it interesting the company is initially limiting potential investors to those who are New York-based and non-US residents. Does residents include corporations as well as individuals? Perhaps, there is a biotech company in New York that has international affiliates/subs, and asset pipeline synergies with AMBS.

Now I certainly don't believe AMBS's Board would agree to sell the company for $5M. I would hope more cash or stock would be part of any sale. However, maybe it could be acquired by another company via a Reg A+ transaction without the buyer having to disclose any terms in a post-sale press release. After all, most people would just assume AMBS was bought for $5M or less because it was a distressed penny stock.